Bank of America Discloses 9.30% Stake in Lakefront Biotherapeutics
LKFT is trading near its 52-week low of $26.42 (4.8% above the low).
Summary
Bank of America Corporation has disclosed a 9.30% stake in Lakefront Biotherapeutics, primarily through equivalent financial instruments, crossing the 5% transparency threshold.
Key Events · Ownership and Investor Activity · LKFT
-
Bank of America Stake Disclosure
Bank of America Corporation reported crossing the 5% ownership threshold in Lakefront Biotherapeutics, now holding a combined 9.30% of voting rights and equivalent financial instruments.
-
Composition of Stake
The stake is primarily comprised of 8.35% in equivalent financial instruments (such as rights to recall, rights of use, call options, and swaps) and 0.95% in direct voting rights.
-
Timing Near 52-Week Low
This disclosure comes as Lakefront Biotherapeutics' stock is trading near its 52-week low of $26.42.
Analysis · LKFT · Life Sciences
Bank of America's disclosure of a significant stake, largely composed of financial instruments, indicates a notable institutional position in Lakefront Biotherapeutics. While not a direct equity investment, this level of involvement by a major financial institution warrants attention, especially as the stock trades near its 52-week low.
At the time of this filing, LKFT was trading at $27.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $26.42 to $37.78. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.